Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284057 | 0.95 | PLK4 (0.34) | PLK4PAK4MAOBRIPK1LMNA | |
| SCHEMBL2127270 | 0.84 | ALDH1A1 (0.37) | HSP90AA1CYP3A4CYP19A1 | |
| SCHEMBL2127428 | 0.84 | KDM4E (0.32) | — | |
| SCHEMBL1282025 | 0.83 | TRPA1 (0.32) | LMNA | |
| SCHEMBL2126333 | 0.83 | KDM4E (0.31) | — | |
| SCHEMBL2132389 | 0.82 | PLK4 (0.34) | PLK4PAK4 | |
| SCHEMBL1282138 | 0.82 | TRPA1 (0.32) | — | |
| SCHEMBL1282032 | 0.82 | TRPA1 (0.31) | — | |
| SCHEMBL2125926 | 0.81 | ALDH1A1 (0.30) | CYP3A4 | |
| SCHEMBL1283973 | 0.81 | ALDH1A1 (0.43) | CYP3A4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108422-A1 | Antifungal 1,2,4-triazolyl Derivatives | BASF SE (DE) | 2012-05-03 | — | — | US | disclosed |
| EP-2443097-A1 | ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES | BASF SE (DE) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010146111-A1 | ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES | BASF SE (DE) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108422-A1 | Antifungal 1,2,4-triazolyl Derivatives | ERG28, CYP51A1, DPM1 | PLK4 1648/4885PAK4 1980/4885MAOB 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.